Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease (May 2023)

Clinical Profile, Health Care Costs, and Outcomes of Patients Hospitalized for Heart Failure With Severely Reduced Ejection Fraction

  • Josephine Harrington,
  • Jie‐Lena Sun,
  • Gregg C. Fonarow,
  • Stephen B. Heitner,
  • Punag H. Divanji,
  • Gary Binder,
  • Larry A. Allen,
  • Brooke Alhanti,
  • Clyde W. Yancy,
  • Nancy M. Albert,
  • Adam D. DeVore,
  • G. Michael Felker,
  • Stephen J. Greene

DOI
https://doi.org/10.1161/JAHA.122.028820
Journal volume & issue
Vol. 12, no. 10

Abstract

Read online

Background Many patients with heart failure (HF) have severely reduced ejection fraction but do not meet threshold for consideration of advanced therapies (ie, stage D HF). The clinical profile and health care costs associated with these patients in US practice is not well described. Methods and Results We examined patients hospitalized for worsening chronic heart failure with reduced ejection fraction ≤40% from 2014 to 2019 in the GWTG‐HF (Get With The Guidelines‐Heart Failure) registry, who did not receive advanced HF therapies or have end‐stage kidney disease. Patients with severely reduced EF defined as EF ≤30% were compared with those with EF 31% to 40% in terms of clinical profile and guideline‐directed medical therapy. Among Medicare beneficiaries, postdischarge outcomes and health care expenditure were compared. Among 113 348 patients with EF ≤40%, 69% (78 589) had an EF ≤30%. Patients with severely reduced EF ≤30% tended to be younger and were more likely to be Black. Patients with EF ≤30% also tended to have fewer comorbidities and were more likely to be prescribed guideline‐directed medical therapy (“triple therapy” 28.3% versus 18.2%, P<0.001). At 12‐months postdischarge, patients with EF ≤30% had significantly higher risk of death (HR, 1.13 [95% CI, 1.08–1.18]) and HF hospitalization (HR, 1.14 [95% CI, 1.09–1.19]), with similar risk of all‐cause hospitalizations. Health care expenditures were numerically higher for patients with EF ≤30% (median US$22 648 versus $21 392, P=0.11). Conclusions Among patients hospitalized for worsening chronic heart failure with reduced ejection fraction in US clinical practice, most patients have severely reduced EF ≤30%. Despite younger age and modestly higher use of guideline‐directed medical therapy at discharge, patients with severely reduced EF face heightened postdischarge risk of death and HF hospitalization.

Keywords